Last edition
News about "CNS therapeutics "
Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration
The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.
CNS Therapeutics | 08/04/2026 | By News Bureau | 103
CBC Group Acquires UCB's Mature Product Portfolio in China
The acquisition marks another successful transaction under CBC's buyout strategy of acquiring key assets from global pharmaceutical companies and a significant step in establishing a market-leading neurology company in China while expanding CBC's portfolio within the region's dynamic pharmaceutical market.
CNS Therapeutics | 03/12/2024 | By Aishwarya | 652
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy